Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The biotech economy

As Old Economy stocks tanked on the Big Board last week, Celera (CRA) demonstrated the new muscle of the biotech space in the New Economy. Stock of the genomics play split 2-1 before the week's trading opened on Tuesday and closed Friday at $250.875, up $92.969 (59 percent) on the week. Pre-split, the stock had most recently eclipsed the $250 barrier on Feb. 15. CRA still has outstanding a follow-on offering, 1.615 million shares not accounting for the split, announced when the split-adjusted price was $101.

Indeed, the sector shrugged off a brief bit of selling on Tuesday to add another 7 percent to the BioCentury 100 index on the week, pulled in another $1.4 billion in financing, and filed equity and debt offerings for $1.2 billion more.

The depth of the biotech turnaround was demonstrated by cancer and infectious disease play Maxim (MMP; SSE:MAXM), which was hammered last summer in Stockholm

Read the full 1502 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE